Tel Aviv University

Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference

Retrieved on: 
Thursday, March 28, 2024
Tel Aviv University, EST, Conference, Research, Good manufacturing practice, FRA, Health Canada, GMP, Ground substance, Safety, API, Good, MDMA, Therapy, Psychedelic drug, Drug development, Pharmaceutical industry

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, proudly announces its role as a Presenting Sponsor at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference.

Key Points: 
  • VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, proudly announces its role as a Presenting Sponsor at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference.
  • The 4th Annual Psychedelic Therapeutics and Drug Development Conference convenes renowned researchers and esteemed leaders from academia, industry, non-profit organizations, and government sectors to explore the challenges and opportunities inherent in the research and development of psychedelic therapies for various health conditions with significant unmet needs.
  • “We believe this conference serves as an excellent platform for us to engage with key stakeholders, exchange ideas, and drive innovation in the field of psychedelic therapeutics,” he added.
  • Optimi delegates will be available at the conference to host networking sessions for those seeking more information about the company's GMP and API drug products.

Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University

Retrieved on: 
Tuesday, March 26, 2024
Tel Aviv University, Interdisciplinarity, Mental health, Research, FRA, Health Canada, Abstract, GMP, Quality, Ground substance, API, MDMA, Psychedelic drug, Pharmaceutical industry

In this collaboration, Optimi will supply IPR-TLV with MDMA, which was made from in-house produced active pharmaceutical ingredient (API), to support the institute's research investigating the effects of MDMA on animal models of alcohol addiction.

Key Points: 
  • In this collaboration, Optimi will supply IPR-TLV with MDMA, which was made from in-house produced active pharmaceutical ingredient (API), to support the institute's research investigating the effects of MDMA on animal models of alcohol addiction.
  • Optimi has received the import permit from IPR-TLV and is in the process of obtaining its export permit from Health Canada.
  • Expected to commence in the summer of 2024 and conclude in late 2025, this study aligns with Optimi's commitment to supplying MDMA to international researchers advancing mental health and addictions research.
  • Commenting on the collaboration, Optimi CEO Bill Ciprick expressed his enthusiasm, stating, "Our agreement with IPR-TLV signifies an exciting entry into the Israeli psychedelics research market for Optimi.

MARZ Releases LipDub AI Beta for Professional Creators to Effortlessly Dub and Lip-Sync Video to Any Language in Minutes at Hollywood Standards

Retrieved on: 
Wednesday, February 21, 2024
Technology, Entertainment, Other Technology, Software, Audio, Video, Other Entertainment, General Entertainment, TV and Radio, Film & Motion Pictures, Artificial Intelligence, Social media, Computer science, Multimedia, AI, Assistant, Marketing, Language, Simon Fraser University, Artifact, VFX, Advertising, Frustration, Lip, Visual computing, Tel Aviv University, Machine learning, Movement, ACM, Workflow, Video game

“LipDub AI will revolutionize content globalization by enabling professional creators to produce video in any number of languages in minutes, not months,” said Jonathan Bronfman, co-founder and CEO of MARZ.

Key Points: 
  • “LipDub AI will revolutionize content globalization by enabling professional creators to produce video in any number of languages in minutes, not months,” said Jonathan Bronfman, co-founder and CEO of MARZ.
  • Using the LipDub AI™ fully automated workflow, professional creators can effortlessly dub and lip-sync their videos to any language at Hollywood standards in minutes.
  • LipDub AI™ is the only solution that gives users the flexibility of using voice actor files or AI generated audio.
  • For more information about LipDub AI™ and to apply to join the beta release waitlist, visit LipDub.ai .

DuPont Renews Collaboration with Silicon Catalyst as a Strategic Ecosystem Partner

Retrieved on: 
Wednesday, March 6, 2024
Artificial intelligence, Tel Aviv University, Silicon, DuPont Experimental Station, Ecosystem, Fine chemical

Silicon Catalyst will continue to provide strategic insight for DuPont into startups developing the next generation of electronic technology, materials and devices.

Key Points: 
  • Silicon Catalyst will continue to provide strategic insight for DuPont into startups developing the next generation of electronic technology, materials and devices.
  • "Engaging with Silicon Catalyst helps DuPont drive innovation through valued insights into emerging opportunities for semiconductor materials and new technologies they can enable.
  • Silicon Catalyst has already introduced DuPont to more than a dozen startups in the materials sector and continues to expand its ecosystem."
  • As a Strategic Ecosystem Partner, DuPont participates in a wide range of activities with Silicon Catalyst, including review of incubator applicants, directed projects for specialized market research, university collaborations and investment opportunities.

BUFFERZONE Security Joins Trust.AI Consortium to Enhance AI-Based Cybersecurity Technologies

Retrieved on: 
Thursday, February 29, 2024
Elbit Systems, Internet, IIA, Artificial intelligence, Tel Aviv University, TEL, Adversarial machine learning, Ariel University, Trust, Acceleration, CPU, Medical device

TEL AVIV, Israel, Feb. 29, 2024 /PRNewswire/ -- BUFFERZONE®, a pioneer in prevention-based cybersecurity solutions, is proud to announce its latest strategic move: joining the prestigious Trust.AI consortium.

Key Points: 
  • TEL AVIV, Israel, Feb. 29, 2024 /PRNewswire/ -- BUFFERZONE®, a pioneer in prevention-based cybersecurity solutions, is proud to announce its latest strategic move: joining the prestigious Trust.AI consortium.
  • BUFFERZONE's inclusion in this esteemed group underscores its commitment to staying at the cutting edge of AI-driven cybersecurity.
  • The IIA investment in Trust.AI consortium members have significantly enhanced Israeli leadership in AI security.
  • BUFFERZONE Security technologies help the consortium tasks to make the internet safer.

X-trodes Receives FDA 510(k) Clearance for Wearable "Skin" Solution that Brings Medical-Grade Electrophysiological Monitoring to the Home

Retrieved on: 
Tuesday, February 20, 2024
Neural engineering, Skin, Doctor of Philosophy, Tel Aviv University, Research, FDA, Cardiology, Food, Sleep, Scientific Reports, EOG, Health, EKG, Gel, EEG, Journal, EMG, Neurology, Environment, Medical imaging

HERZLIYA, Israel, Feb. 20, 2024 /PRNewswire/ -- X-trodes, a bio-convergence company bringing wireless monitoring solutions to the home environment, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for X-trodes' Smart Skin solution (marketed as X-trodes System M), a new wireless wearable technology for advanced electrophysiological monitoring.  

Key Points: 
  • The discreet patches are easy to apply and comfortable to wear, conforming to the body without requiring gels, wires or uncomfortable solutions.
  • The FDA clearance follows successful completion of an extensive scientific assessment that evaluated the accuracy and consistency of X-trodes' system.
  • "Gaining FDA clearance affirms the value of this technology and its potential to improve health and wellness through access to real-time electrophysiological data.
  • Electrophysiological monitoring has traditionally been restricted to clinics, requiring cumbersome hardware and controlled environments to acquire highly sensitive physiological signals.

X-trodes Receives FDA 510(k) Clearance for Wearable "Skin" Solution that Brings Medical-Grade Electrophysiological Monitoring to the Home

Retrieved on: 
Tuesday, February 20, 2024
Neural engineering, Skin, Doctor of Philosophy, Tel Aviv University, Research, FDA, Cardiology, Food, Sleep, Scientific Reports, EOG, Health, EKG, Gel, EEG, Journal, EMG, Neurology, Environment, Medical imaging

HERZLIYA, Israel, Feb. 20, 2024 /PRNewswire/ -- X-trodes, a bio-convergence company bringing wireless monitoring solutions to the home environment, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for X-trodes' Smart Skin solution (marketed as X-trodes System M), a new wireless wearable technology for advanced electrophysiological monitoring.  

Key Points: 
  • The discreet patches are easy to apply and comfortable to wear, conforming to the body without requiring gels, wires or uncomfortable solutions.
  • The FDA clearance follows successful completion of an extensive scientific assessment that evaluated the accuracy and consistency of X-trodes' system.
  • "Gaining FDA clearance affirms the value of this technology and its potential to improve health and wellness through access to real-time electrophysiological data.
  • Electrophysiological monitoring has traditionally been restricted to clinics, requiring cumbersome hardware and controlled environments to acquire highly sensitive physiological signals.

Shamir Medical Center Reveals New Long-Term Results from Long COVID Study to Highlight Positive Impact on Symptoms Resulting from Hyperbaric Oxygen Therapy

Retrieved on: 
Thursday, February 15, 2024
Regeneration, Metabolism, Research, Randomized controlled trial, Tel Aviv University, Inflammation, Hyperbaric medicine, Quality of life, Neuron, Sleep, Psychiatry, Thrombosis, Shamir Medical Center, Cytokine, Fatigue, COVID, Patient, Gene, HBOT, Tissue, Pressure, Pharmaceutical industry

In a previous randomized controlled trial, significant improvements in cognitive, psychiatric, fatigue, sleep, and pain symptoms among long COVID patients who underwent a unique protocol of hyperbaric oxygen therapy were documented.

Key Points: 
  • In a previous randomized controlled trial, significant improvements in cognitive, psychiatric, fatigue, sleep, and pain symptoms among long COVID patients who underwent a unique protocol of hyperbaric oxygen therapy were documented.
  • This longitudinal follow-up included 31 patients from the original study, who were treated with 40 daily sessions of HBOT.
  • The results indicate HBOT can improve the quality of life, quality of sleep, psychiatric and pain symptoms of patients suffering from long COVID.
  • By delivering high oxygen concentrations, HBOT can enhance oxygen delivery to tissues, resulting in recovery of injured tissues permanent improvement.

Augmedix Names Tomer Levy as New Senior Vice President of Engineering

Retrieved on: 
Tuesday, February 13, 2024
Cloud, SAN, Hospital, Senior, AI, Tel Aviv University, Change Healthcare, MBA, Economics, Google Cloud Platform

SAN FRANCISCO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, today announced that Tomer Levy joined the company in January 2024 in the newly-created Senior Vice President of Engineering role.

Key Points: 
  • SAN FRANCISCO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, today announced that Tomer Levy joined the company in January 2024 in the newly-created Senior Vice President of Engineering role.
  • “We are thrilled to have Tomer join Augmedix as we continue to push the boundaries of AI-powered medical documentation technology to alleviate administrative burden,” said Manny Krakaris, CEO of Augmedix.
  • “Tomer has a distinguished career managing complex, global infrastructures, and having him on the Augmedix team will allow us to optimize engineering performance, streamline product development, and accelerate scalability to health systems across the nation.
  • Tomer's ownership of our production systems will enable our CTO, Saurav Chatterjee, to focus on pushing the frontiers of AI technology embedded in our platform.”
    Prior to joining Augmedix, Levy most recently served as Senior Vice President of Research and Development at Change Healthcare.

New Report Analyzes Key Action in Fighting Antisemitism - Finds US Colleges and Universities Failing to Take Necessary Steps

Retrieved on: 
Monday, January 22, 2024
IHRA, Student, Learning, Islamism, Rockefeller Center, City, Partnership, School, UN, George Washington University, University, Cooper Union, Harvard University, Government, Boston University, Hamas, International Holocaust Remembrance Alliance, Movement, Cornell University, Tel Aviv University, Violence, Annual report, The Holocaust, Tourism

WASHINGTON, Jan. 22, 2024 /PRNewswire-PRWeb/ -- Since Hamas' massacre in Israel on October 7, Jewish communities globally have faced an increase in discrimination, harassment, and violence, underscoring the importance of recognizing and clearly defining antisemitism.

Key Points: 
  • Combat Antisemitism Movement Has Now Tracked Over 1,200 Global Adoptions of the IHRA Working Definition of Antisemitism.
  • This is the third annual report CAM has released on the global adoption of the IHRA working definition since the definition was first adopted in 2016.
  • At the national level, 45 countries, including the U.S. and most Western democracies, have adopted the IHRA working definition.
  • Virginia is just one of 34 U.S. states that have so far adopted the IHRA working definition.